交易 Zentalis Pharmaceuticals - ZNTL CFD
加入收藏夹- 概括
- 曆史數據
- 活動
- 收入報表
- 資産負債表
- 現金流
交易條件
价差 | 0.19 | ||||||||
多头隔夜费
多头隔夜费
前往平台 | -0.026179% | ||||||||
空头隔夜费
空头隔夜费
前往平台 | 0.003957% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 5% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Zentalis Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
“C”分數表示在公開報告重大 ESG 數據方面令人滿意的相對 ESG 表現和適度的透明度。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 關閉 | 更改 | 變化 (%) | 打開 | 高 | 低 |
---|---|---|---|---|---|---|
Apr 17, 2024 | 12.61 | -0.18 | -1.41% | 12.79 | 13.24 | 12.52 |
Apr 16, 2024 | 12.83 | 0.11 | 0.86% | 12.72 | 13.28 | 12.57 |
Apr 15, 2024 | 13.14 | -0.10 | -0.76% | 13.24 | 13.69 | 12.88 |
Apr 12, 2024 | 13.32 | 0.44 | 3.42% | 12.88 | 13.98 | 12.79 |
Apr 11, 2024 | 13.34 | -0.82 | -5.79% | 14.16 | 14.26 | 13.05 |
Apr 10, 2024 | 14.64 | -0.08 | -0.54% | 14.72 | 14.99 | 14.18 |
Apr 9, 2024 | 15.66 | 1.32 | 9.21% | 14.34 | 15.70 | 14.24 |
Apr 8, 2024 | 14.55 | -0.31 | -2.09% | 14.86 | 15.01 | 14.20 |
Apr 5, 2024 | 15.03 | 0.11 | 0.74% | 14.92 | 15.24 | 14.16 |
Apr 4, 2024 | 15.21 | -0.14 | -0.91% | 15.35 | 16.14 | 15.10 |
Apr 3, 2024 | 14.87 | 0.39 | 2.69% | 14.48 | 15.63 | 13.68 |
Apr 2, 2024 | 14.34 | -1.18 | -7.60% | 15.52 | 15.60 | 13.98 |
Apr 1, 2024 | 16.03 | 0.68 | 4.43% | 15.35 | 16.19 | 14.80 |
Mar 28, 2024 | 15.67 | 0.63 | 4.19% | 15.04 | 16.01 | 15.01 |
Mar 27, 2024 | 15.12 | 1.03 | 7.31% | 14.09 | 15.15 | 13.83 |
Mar 26, 2024 | 14.03 | 0.83 | 6.29% | 13.20 | 14.29 | 13.20 |
Mar 25, 2024 | 13.51 | -0.01 | -0.07% | 13.52 | 13.95 | 13.23 |
Mar 22, 2024 | 13.55 | -0.03 | -0.22% | 13.58 | 13.78 | 13.31 |
Mar 21, 2024 | 13.59 | 0.34 | 2.57% | 13.25 | 14.13 | 13.24 |
Mar 20, 2024 | 13.61 | -0.07 | -0.51% | 13.68 | 13.78 | 13.05 |
Zentalis Pharmaceuticals Events
时间(协调世界时) (UTC) | 国家 | 事件 |
---|---|---|
Wednesday, May 8, 2024 | ||
时间(协调世界时) (UTC) 12:30 | 国家 US
| 事件 Q1 2024 Zentalis Pharmaceuticals Inc Earnings Release Q1 2024 Zentalis Pharmaceuticals Inc Earnings ReleaseForecast(预报) -上一页 - |
Friday, June 14, 2024 | ||
时间(协调世界时) (UTC) 13:30 | 国家 US
| 事件 Zentalis Pharmaceuticals Inc Annual Shareholders Meeting Zentalis Pharmaceuticals Inc Annual Shareholders MeetingForecast(预报) -上一页 - |
Wednesday, August 7, 2024 | ||
时间(协调世界时) (UTC) 12:30 | 国家 US
| 事件 Q2 2024 Zentalis Pharmaceuticals Inc Earnings Release Q2 2024 Zentalis Pharmaceuticals Inc Earnings ReleaseForecast(预报) -上一页 - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
總收入 | 0 | 0 | 0 | 0 | 0.014 |
收入 | 0 | 0.014 | |||
總營業費用 | 227.287 | 164.96 | 118.787 | 46.845 | 23.797 |
銷售/一般/行政費用,總計 | 54.553 | 40.941 | 33.886 | 8.459 | 4.876 |
研究與開發 | 172.734 | 166.801 | 84.901 | 38.386 | 18.921 |
營業收入 | -227.287 | -164.96 | -118.787 | -46.845 | -23.783 |
利息收入(費用),非經營淨值 | 5.987 | 0.401 | 0.683 | 0.498 | 0.355 |
其他,淨值 | -0.016 | 0 | |||
稅前淨收入 | -221.3 | -164.559 | -118.104 | -46.363 | -23.428 |
稅後淨收入 | -220.831 | -164.262 | -118.548 | -46.378 | -23.432 |
少數股東權益 | 0.307 | 7.368 | 0.707 | 0.715 | 2.365 |
未計算非常項目前的淨收益 | -236.806 | -158.725 | -117.841 | -45.663 | -21.067 |
淨收入 | -236.806 | -158.725 | -117.841 | -45.663 | -21.067 |
普通股股東可獲收益 (不含非經常性項目) | -236.806 | -158.725 | -117.841 | -45.663 | -21.067 |
普通股股東可獲收益 (含非經常性項目) | -236.806 | -158.725 | -117.841 | -45.663 | -21.067 |
攤薄淨收入 | -236.806 | -158.725 | -117.841 | -45.663 | -21.067 |
攤薄後加權平均股 | 52.857 | 42.688 | 28.113 | 34.5015 | 34.5015 |
扣除特別項目的每股攤薄盈利 | -4.48013 | -3.71826 | -4.19169 | -1.32351 | -0.61061 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
每股正常攤薄盈利 | -4.48013 | -4.29754 | -4.19169 | -1.32351 | -0.61061 |
異常費用(收入) | 0 | -42.782 | |||
Equity In Affiliates | -16.282 | -1.831 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
總收入 | 0 | 0 | 0 | 0 | 0 |
總營業費用 | 103.916 | 64.953 | 51.754 | 54.193 | 63.461 |
銷售/一般/行政費用,總計 | 15.664 | 11.369 | 11.138 | 12.012 | 19.636 |
研究與開發 | 88.252 | 48.584 | 40.616 | 42.181 | 43.825 |
營業收入 | -103.916 | -64.953 | -51.754 | -54.193 | -63.461 |
利息收入(費用),非經營淨值 | 4.451 | 4.109 | 3.232 | 1.905 | 0.424 |
其他,淨值 | |||||
稅前淨收入 | -99.465 | -60.844 | -48.522 | -52.288 | -63.037 |
稅後淨收入 | -98.86 | -60.952 | -48.162 | -52.129 | -63.054 |
少數股東權益 | 0.037 | 0.043 | 0.013 | 0.099 | 0.035 |
未計算非常項目前的淨收益 | -112.527 | -63.219 | -54.971 | -54.401 | -68.357 |
淨收入 | -112.527 | -63.219 | -54.971 | -54.401 | -68.357 |
普通股股東可獲收益 (不含非經常性項目) | -112.527 | -63.219 | -54.971 | -54.401 | -68.357 |
普通股股東可獲收益 (含非經常性項目) | -112.527 | -63.219 | -54.971 | -54.401 | -68.357 |
攤薄淨收入 | -112.527 | -63.219 | -54.971 | -54.401 | -68.357 |
攤薄後加權平均股 | 60.79 | 59.277 | 58.134 | 56.807 | 51.117 |
扣除特別項目的每股攤薄盈利 | -1.85108 | -1.0665 | -0.94559 | -0.95765 | -1.33727 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | -1.85108 | -1.01167 | -0.94559 | -0.95765 | -1.33727 |
異常費用(收入) | 0 | 5 | 0 | 0 | |
Equity In Affiliates | -13.704 | -2.31 | -6.822 | -2.371 | -5.338 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流動資産總額 | 451.933 | 350.77 | 345.104 | 68.891 | 26.677 |
現金和短期投資 | 437.371 | 339.887 | 338.505 | 67.246 | 25.154 |
現金等價物 | 43.069 | 59.714 | 54.951 | 67.246 | 25.154 |
應收賬款總額,淨額 | 6.382 | 0.004 | 0.417 | 0.14 | 0.917 |
應收賬款 - 貿易,淨額 | 0.004 | 0.417 | 0.14 | 0.917 | |
預付的費用 | 7.521 | 10.636 | 6.182 | 1.505 | 0.606 |
總資産 | 539.31 | 454.507 | 365.555 | 87.481 | 40.998 |
物業/廠房/設備,總計 - 淨額 | 50.078 | 52.839 | 3.619 | 2.836 | 0.26 |
物業/廠房/設備,總計 - 總額 | 52.138 | 53.631 | 3.869 | 3.003 | 0.316 |
累計折舊,總計 | -2.06 | -0.792 | -0.25 | -0.167 | -0.056 |
商譽,淨額 | 3.736 | 3.736 | 3.736 | 3.736 | 3.736 |
無形資産,淨額 | 0 | 8.8 | 8.8 | 8.8 | |
其他長期資産,總計 | 12.35 | 9.667 | 4.296 | 3.218 | 1.525 |
流動負債總額 | 56.647 | 43.944 | 28.601 | 14.897 | 6.208 |
應付賬款 | 11.247 | 11.59 | 8.661 | 4.289 | 3.431 |
預提費用 | 45.016 | 31.383 | 19.53 | 10.608 | 2.554 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 0.384 | 0.971 | 0.41 | 0 | 0.223 |
負債總額 | 105.507 | 90.553 | 56.973 | 25.881 | 16.228 |
長期債務總額 | 0 | 0 | 0 | 0 | 0 |
遞延所得稅 | 0.853 | 1.622 | 2.48 | 2.463 | 2.463 |
少數股權 | 0.221 | 0.528 | 24.795 | 6.821 | 7.536 |
其他負債,總計 | 47.786 | 44.459 | 1.097 | 1.7 | 0.021 |
總權益 | 433.803 | 363.954 | 308.582 | 61.6 | 24.77 |
Redeemable Preferred Stock | 0 | 0 | 0 | 141.706 | 59.83 |
普通股 | 0.059 | 0.045 | 0.041 | 2.887 | 2.27 |
留存收益(累計赤字) | -596.365 | -359.559 | -200.834 | -82.993 | -37.33 |
總負債和股東權益 | 539.31 | 454.507 | 365.555 | 87.481 | 40.998 |
已發行普通股總數 | 59.2803 | 45.4908 | 41.0403 | 34.5015 | 34.5015 |
短期投資 | 394.302 | 280.173 | 283.554 | ||
額外實收資本 | 1031.46 | 723.593 | 509.339 | ||
Unrealized Gain (Loss) | -1.353 | -0.125 | 0.036 | ||
其他流動資産,總計 | 0.659 | 0.243 | |||
長期投資 | 21.213 | 37.495 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
流動資産總額 | 563.929 | 410.226 | 451.933 | 433.89 | |
現金和短期投資 | 552.986 | 392.519 | 437.371 | 421.726 | |
現金等價物 | 266.558 | 36.28 | 43.069 | 42.551 | |
短期投資 | 286.428 | 356.239 | 394.302 | 379.175 | |
應收賬款總額,淨額 | 1.81 | 8.293 | |||
應收賬款 - 貿易,淨額 | |||||
預付的費用 | 8.222 | 8.474 | 14.562 | 12.164 | |
總資産 | 621.444 | 489.342 | 539.31 | 529.193 | |
物業/廠房/設備,總計 - 淨額 | 43.234 | 44.355 | 50.078 | 50.673 | |
物業/廠房/設備,總計 - 總額 | 45.998 | 47.448 | 52.138 | 52.374 | |
累計折舊,總計 | -2.764 | -3.093 | -2.06 | -1.701 | |
商譽,淨額 | 3.736 | 3.736 | 3.736 | 3.736 | |
無形資産,淨額 | |||||
其他長期資産,總計 | 10.545 | 12.122 | 12.35 | 12.859 | |
流動負債總額 | 51.759 | 56.358 | 56.647 | 54.061 | |
應付賬款 | 12.305 | 12.818 | 11.247 | 9.82 | |
預提費用 | 38.832 | 43.115 | 45.016 | 43.893 | |
應付票據/短期債務 | 0 | 0 | 0 | 0 | |
其他流動負債,總計 | 0.622 | 0.425 | 0.384 | 0.348 | |
負債總額 | 98.303 | 103.855 | 105.507 | 100.689 | |
長期債務總額 | 0 | 0 | 0 | 0 | |
遞延所得稅 | 0 | 0.756 | 0.853 | 1.225 | |
少數股權 | 0.141 | 0.178 | 0.221 | 0.234 | |
其他負債,總計 | 46.403 | 46.563 | 47.786 | 45.169 | |
總權益 | 523.141 | 385.487 | 433.803 | 428.504 | |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
普通股 | 0.07 | 0.059 | 0.059 | 0.057 | |
額外實收資本 | 1295.52 | 1045.57 | 1031.46 | 972.111 | |
留存收益(累計赤字) | -772.111 | -659.584 | -596.365 | -541.394 | |
其他權益,總計 | -0.338 | ||||
總負債和股東權益 | 621.444 | 489.342 | 539.31 | 529.193 | |
已發行普通股總數 | 70.6037 | 59.4423 | 59.2803 | 57.0023 | |
其他流動資産,總計 | 0.911 | 0.94 | 0 | 0 | |
長期投資 | 0 | 18.903 | 21.213 | 28.035 | |
Unrealized Gain (Loss) | -0.556 | -1.353 | -2.27 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -237.113 | -166.093 | -118.548 | -46.378 | -23.432 |
经营活动产生的现金 | -163.751 | -154.093 | -86.825 | -39.143 | -24.251 |
经营活动产生的现金 | 1.426 | 0.544 | 0.16 | 0.111 | 0.051 |
非现金物品 | 59.453 | -5.101 | 23.702 | 0.617 | 0.308 |
Cash Taxes Paid | 0.012 | 0.02 | 0.018 | 0.015 | 0.004 |
营运资金的变化 | 13.252 | 16.557 | 7.844 | 6.507 | -1.178 |
投资活动产生的现金 | -114.18 | -18.115 | -284.832 | -0.352 | -0.227 |
资本支出 | -2.548 | -6.107 | -0.758 | -0.352 | -0.227 |
融资活动产生的现金 | 261.043 | 178.521 | 360.439 | 81.83 | 9.472 |
融资现金流项目 | 0 | -1.146 | 18.424 | -0.046 | 0 |
股票的发行(报废),净额 | 261.043 | 179.667 | 342.015 | 81.876 | 9.472 |
现金净变化 | -16.888 | 6.313 | -11.218 | 42.335 | -15.006 |
Deferred Taxes | -0.769 | 0 | 0.017 | ||
其他投资现金流量项目,总计 | -111.632 | -12.008 | -284.074 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -63.262 | -237.113 | -182.129 | -127.629 | -59.237 |
Cash From Operating Activities | -49.283 | -163.751 | -126.422 | -93.223 | -50.196 |
Cash From Operating Activities | 0.36 | 1.426 | 1.067 | 0.692 | 0.344 |
Non-Cash Items | 17.735 | 59.453 | 45.371 | 34.074 | 12.044 |
Changes in Working Capital | -4.019 | 13.252 | 9.269 | -0.36 | -3.347 |
Cash From Investing Activities | 42.121 | -114.18 | -102.286 | -122.304 | 19.796 |
Capital Expenditures | -2.548 | -2.388 | -0.728 | -0.45 | |
Other Investing Cash Flow Items, Total | 42.121 | -111.632 | -99.898 | -121.576 | 20.246 |
Cash From Financing Activities | 0.373 | 261.043 | 211.302 | 210.713 | 1.258 |
Financing Cash Flow Items | 0 | 0 | |||
Issuance (Retirement) of Stock, Net | 0.373 | 261.043 | 211.302 | 210.713 | 1.258 |
Net Change in Cash | -6.789 | -16.888 | -17.406 | -4.814 | -29.142 |
Deferred Taxes | -0.097 | -0.769 |
差價合約交易計算器
如果您在特定日期(選取一個日期)開立差價合約交易並在不同日期(選取一個日期)關閉交易,計算您的假設盈虧。
交易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
打開
關閉
做空 做多
Zentalis Pharmaceuticals Company profile
关于 Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc.是一家处于临床阶段的生物制药公司,致力于发现和开发针对癌症基本生物途径的小分子治疗方法。 该公司正在开发一个候选产品管道,重点是有效的肿瘤学目标。 其主要候选产品ZN-c5是一种口服的选择性雌激素受体降解剂。 ZN-c5正在进行I/II期临床试验,用于治疗雌激素受体阳性、人类表皮生长因子受体2阴性的疾病;ZN-c3是一种蛋白酪氨酸激酶WEE1的抑制剂。 ZN-c3正处于治疗晚期实体瘤的I/II期临床试验。 其其他产品包括ZN-d5,一种B细胞淋巴瘤2的选择性抑制剂,正在开发用于治疗非霍奇金淋巴瘤和急性骨髓性白血病;以及ZN-e4,一种变异表皮生长因子受体的不可逆抑制剂,正在进行治疗晚期非小细胞肺癌的I/II期临床试验。
Industry: | Bio Therapeutic Drugs |
1359 Broadway, Suite 801
NEW YORK
NEW YORK 10018
US
收入報表
- Annual
- Quarterly
人們也觀看
还在找一位您可以信任的经纪商吗?
加入成为全球610,000万多名交易者的一份子,选择利用Capital.com进行交易吧。